This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Optimer Soars on Antibiotic Data

Optimer Pharmaceuticals (OPTR) proves that even in a bear market, small biotech stocks are still capable of doubling in price overnight.

Shares of Optimer, a pick in my Biotech Select model portfolio, soared 90% Monday night after the San Diego-based company reported positive top-line results from a pivotal phase III study of its experimental antibiotic OPT-80 in patients infected with the hospital-borne infection Clostridium difficile.

OPT-80 achieved cure rates that are statistically equivalent to Vancocin, the only Food and Drug Administration-approved treatment for Clostridium difficile, or C. diff for short. Better yet, OPT-80 significantly reduced the recurrence of C. diff compared to Vancocin, which is marketed by Viropharma (VPHM - Get Report).

C. diff is a scary bacterial superbug that causes severe abdominal pain, bloating and diarrhea. In severe cases, the C. diff bug can rupture colons, cause blood infections and lead to death.

Like the better publicized staph infection known as MRSA, the rate of new and recurrent C. diff infections are on the rise across the U.S. and the rest of the world. Hospitals are struggling to keep new infections under control. Two antibiotics used to treat C. diff -- Vancocin and metronidazole (used off label) -- do a relatively good job of curing patients, but the relapse rate -- once treatment ends -- is high.

Biotech Select

Optimer's experimental drug OPT-80 is designed to match the cure rate of the current C. diff drugs with a more convenient twice-daily dosing schedule. More importantly, earlier data suggests that OPT-80 could significantly cut the recurrence rate of C. diff infections.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
VPHM $49.96 -0.02%
OPTR $0.00 0.00%
BDSI $7.90 0.00%
CYTK $5.51 0.00%
GENE $4.46 0.00%

Markets

DOW 17,928.20 -142.20 -0.79%
S&P 500 2,089.46 -25.03 -1.18%
NASDAQ 4,939.3270 -77.6020 -1.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs